Bio Medica Laboratories IPO
Bookbuilding IPO | ₹52.00 Cr | Listing at NSE SME
Closed
IPO Open
Thu, May 21, 2026
IPO Close
Mon, May 25, 2026
Price Band
₹132.00 to ₹139.00
Market Cap (Pre-IPO)
₹174.79 Cr
IPO Details
| IPO Date | May 21, 2026 to May 25, 2026 |
| Listing Date | Tentative: May 29, 2026 |
| Face Value | ₹10.00 per share |
| Price Band | ₹132.00 to ₹139.00 |
| Lot Size | 1000 Shares (Minimum: ₹139,000.00) |
| Sale Type | Offer For Sale + Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Issue Size | ₹52.00 Crores |
| Total Shares Offered | 3,772,000 shares |
| Fresh Issue | 3,206,000 shares |
| Offer For Sale | 376,998 shares |
Bio Medica Laboratories IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 36,000 |
| Retail Shares Offered | 17,92,000 |
| NII Shares Offered | 17,55,000 |
Bio Medica Laboratories IPO Lot Size
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹278,000 |
| Retail (Max) | 2 | 2,000 | ₹278,000 |
| S-HNI (Min) | 3 | 3,000 | ₹417,000 |
| S-HNI (Max) | 7 | 7,000 | ₹973,000 |
| B-HNI (Min) | 8 | 8,000 | ₹1,112,000 |
Bio Medica Laboratories Financial Information (Restated Consolidated)
| Period Ended | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| ROE (Return on Equity) | 99.59% |
| ROCE (Return on Capital Employed) | 48.20% |
| Debt/Equity | 1.02 |
| RoNW (Return on Net Worth) | 99.59% |
| PAT Margin (Profit After Tax Margin) | 25.64% |
| EBITDA Margin | 39.83% |
| Price to Book Value | 8.66 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 10.67 | 10.33 |
| P/E (x) | 13.03 | 13.45 |
| Promoter Holding | 99.99% | - |
Company Promoters
- Mr. Mukesh Mehta and Mr. Pradeep Mehta are the company promoters.
Company Overview
Bio Medica Laboratories – Company Overview
- Incorporated in August 2015, Bio Medica Laboratories specializes in the manufacturing of pharmaceutical parenteral formulations for human and veterinary healthcare.
Core Segments
- Liquid Injectables: 58 products in single-dose and multi-dose formats
- Dry Powder Injectables: 15 injectable products
- The company manufactures ethical drugs, generic medicines, and OTC pharmaceutical products.
- It operates on a B2B contract manufacturing model, developing formulations as per client requirements and specifications.
- The company focuses on injectable pharmaceutical solutions, catering to both human and veterinary healthcare sectors.
- It holds GMP and GLP certifications issued by the Food & Drugs Administration, Madhya Pradesh, ensuring quality and compliance standards.
- The company operates two manufacturing facilities in Indore, Madhya Pradesh.
Company Strengths
- Multi-product capability and diversified product portfolio
- Experienced promoters, management and employees.
- Quality assurance
- Established client relationship
Use of Proceeds
| 1) | Repayment of loan | 6.50 |
| 2) | Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 28.50 |
| 3) | General Corporate Purposes | |
| Total | 35.00 |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Bio Medica Laboratories IPO Peer Comparison
Bio Medica Laboratories peer comparison with similar listed entities. (As on March 31, 2025)| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | 10.67 | - | 16.05 | - | 99.59 | - | Standalone |
| Zenotech Laboratories Limited | 0.92 | - | 15.76 | - | 6.01 | 4.13 | Standalone |
| Shukra Pharmaceuticals Limited | 0.22 | - | 1.43 | 47.57 | 15.90 | 20.00 | Standalone |
Quick Info
| Sector | Pharmaceuticals & Healthcare |
| Exchange | NSE SME |
| Market Cap (Pre-IPO) | ₹174.79 Cr |
Important Dates
| IPO Open | May 21, 2026 |
| IPO Close | May 25, 2026 |
| Allotment Date | May 26, 2026 |
| Credit to Demat | May 27, 2026 |
| Listing Date | Tentative: May 29, 2026 |
Lead Manager(s)
Narnolia Financial Services Ltd.
Registrar
Skyline Financial Services Pvt.Ltd.
02228511022
Description
- IPO Type: Book build issue aggregating to ₹52.43 crores.
- Issue Structure: Combination of:
- Fresh Issue: 0.34 crore shares aggregating to ₹47.19 crores
- Offer for Sale (OFS): 0.04 crore shares aggregating to ₹5.24 crores
- IPO Dates: The issue opens on May 21, 2026 and closes on May 25, 2026.
- Allotment Date: Expected to be finalized on May 26, 2026.
- Listing Details: Shares are proposed to be listed on the SME platform of the National Stock Exchange of India (NSE SME) with a tentative listing date of May 29, 2026.
- Retail Investment Requirement: Minimum 2 lots (2,000 shares) amounting to approximately ₹2,78,000 (at upper price band).
- HNI Investment Requirement: Minimum 3 lots (3,000 shares) totaling around ₹4,17,000.
- IPO Price Band: ₹132 to ₹139 per equity share.
- Lot Size: 1,000 shares per lot.
This IPO offers investors an opportunity to participate in the pharmaceutical and laboratory healthcare sector, subject to market risks.